Roche overhauls Spark gene therapy unit, recording $2.4B in full impairment

Roche has recently launched a “fundamental reorganization” of Spark Therapeutics, the gene therapy unit the Swiss pharma bought for $4.3 billion in 2019.

Roche described the restructuring in its annual finance report published in late January. The move is part of the company’s wider strategic change across its pharma division, a company spokesperson told Fierce Pharma.